Literature DB >> 20134482

Skp2B attenuates p53 function by inhibiting prohibitin.

Harish Chander1, Max Halpern, Lois Resnick-Silverman, James J Manfredi, Doris Germain.   

Abstract

The F-box protein Skp2 and its isoform Skp2B are both overexpressed in breast cancers. Skp2 alters the activity of p53 by inhibiting its interaction with p300 and by promoting p300 degradation. Here, we report that Skp2B also attenuates the activity of p53; however, this effect is independent of p300, suggesting that another mechanism might be involved. Prohibitin, a protein reported to activate p53, was isolated in a two-hybrid screen with the carboxy-terminal domain unique to Skp2B. We observed that prohibitin is a new substrate of Skp2B and that the degradation of prohibitin is responsible for the attenuated activity of p53 in cells overexpressing Skp2B. Furthermore, we show that the activity of p53 is reduced in the mammary glands of Skp2B transgenic mice. This study indicates that both Skp2 and Skp2B attenuate p53 activity through different pathways, suggesting that amplification of the Skp2 locus represents a powerful mechanism to attenuate p53 function in cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20134482      PMCID: PMC2838694          DOI: 10.1038/embor.2010.2

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  13 in total

1.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27.

Authors:  A C Carrano; E Eytan; A Hershko; M Pagano
Journal:  Nat Cell Biol       Date:  1999-08       Impact factor: 28.824

2.  Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment.

Authors:  C Kuperwasser; J Pinkas; G D Hurlbut; S P Naber; D J Jerry
Journal:  Cancer Res       Date:  2000-05-15       Impact factor: 12.701

3.  Delayed involution of the mammary epithelium in BALB/c-p53null mice.

Authors:  D J Jerry; C Kuperwasser; S R Downing; J Pinkas; C He; E Dickinson; S Marconi; S P Naber
Journal:  Oncogene       Date:  1998-11-05       Impact factor: 9.867

Review 4.  P53+/- hemizygous knockout mouse: overview of available data.

Authors:  R D Storer; J E French; J Haseman; G Hajian; E K LeGrand; G G Long; L A Mixson; R Ochoa; J E Sagartz; K A Soper
Journal:  Toxicol Pathol       Date:  2001       Impact factor: 1.902

5.  A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development.

Authors:  D J Jerry; F S Kittrell; C Kuperwasser; R Laucirica; E S Dickinson; P J Bonilla; J S Butel; D Medina
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

6.  Differential expression of the F-box proteins Skp2 and Skp2B in breast cancer.

Authors:  Susanne Radke; Andreja Pirkmaier; Doris Germain
Journal:  Oncogene       Date:  2005-05-12       Impact factor: 9.867

Review 7.  Prohibitin: a potential target for new therapeutics.

Authors:  Suresh Mishra; Leigh C Murphy; B L Gregoire Nyomba; Liam J Murphy
Journal:  Trends Mol Med       Date:  2005-04       Impact factor: 11.951

8.  p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis.

Authors:  L Sivaraman; O M Conneely; D Medina; B W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

9.  Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling.

Authors:  Gina Fusaro; Piyali Dasgupta; Shipra Rastogi; Bharat Joshi; Srikumar Chellappan
Journal:  J Biol Chem       Date:  2003-09-18       Impact factor: 5.157

10.  Transcriptional responses to estrogen and progesterone in mammary gland identify networks regulating p53 activity.

Authors:  Shaolei Lu; Klaus A Becker; Mary J Hagen; Haoheng Yan; Amy L Roberts; Lesley A Mathews; Sallie S Schneider; Hava T Siegelmann; Kyle J MacBeth; Stephen M Tirrell; Jeffrey L Blanchard; D Joseph Jerry
Journal:  Endocrinology       Date:  2008-06-12       Impact factor: 4.736

View more
  14 in total

1.  Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation.

Authors:  Wenwen Zhang; Lulu Cao; Zijia Sun; Jing Xu; Lin Tang; Weiwei Chen; Jiayan Luo; Fang Yang; Yucai Wang; Xiaoxiang Guan
Journal:  Cell Cycle       Date:  2016-04-25       Impact factor: 4.534

2.  Prohibitin promotes androgen receptor activation in ER-positive breast cancer.

Authors:  Pengying Liu; Yumei Xu; Wenwen Zhang; Yan Li; Lin Tang; Weiwei Chen; Jing Xu; Qian Sun; Xiaoxiang Guan
Journal:  Cell Cycle       Date:  2017-03-08       Impact factor: 4.534

Review 3.  Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases.

Authors:  Dong Wang; Redouane Tabti; Sabria Elderwish; Hussein Abou-Hamdan; Amel Djehal; Peng Yu; Hajime Yurugi; Krishnaraj Rajalingam; Canan G Nebigil; Laurent Désaubry
Journal:  Cell Mol Life Sci       Date:  2020-02-15       Impact factor: 9.261

4.  p53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers.

Authors:  Bao Kong; Qi Wang; Ella Fung; Kai Xue; Benjamin K Tsang
Journal:  J Biol Chem       Date:  2014-08-11       Impact factor: 5.157

Review 5.  Recent advances in SCF ubiquitin ligase complex: Clinical implications.

Authors:  Nana Zheng; Quansheng Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2016-05-05

Review 6.  The role and therapeutic potential of prohibitin in disease.

Authors:  Arianne L Theiss; Shanthi V Sitaraman
Journal:  Biochim Biophys Acta       Date:  2011-02-04

7.  Prohibitin attenuates colitis-associated tumorigenesis in mice by modulating p53 and STAT3 apoptotic responses.

Authors:  Arwa S Kathiria; William L Neumann; Jennifer Rhees; Erin Hotchkiss; Yulan Cheng; Robert M Genta; Stephen J Meltzer; Rhonda F Souza; Arianne L Theiss
Journal:  Cancer Res       Date:  2012-08-06       Impact factor: 12.701

8.  Skp2 and Skp2B team up against Rb and p53.

Authors:  Doris Germain
Journal:  Cell Div       Date:  2011-01-21       Impact factor: 5.130

9.  Skp2B overexpression alters a prohibitin-p53 axis and the transcription of PAPP-A, the protease of insulin-like growth factor binding protein 4.

Authors:  Harish Chander; Max Halpern; Lois Resnick-Silverman; James J Manfredi; Doris Germain
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

10.  p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Authors:  Lindi Chen; Deborah A Tweddle
Journal:  Front Oncol       Date:  2012-11-28       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.